Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• The chimeric state post-allogeneic stem cell transplantation offers a unique opportunity for adoptive immunotherapy.
• Donor-derived cells can be leveraged to combat hematologic malignancies.

Purpose of the Study:

• To review recent advancements in donor cell transfusions for treating hematologic malignancies.
• To analyze the types of diseases treated, cells utilized, and their origins.

Main Methods:

• Review of studies on donor lymphocyte infusions (DLIs) and other donor cell therapies.
• Analysis of various donor sources, including HLA-identical siblings, unrelated donors, and haploidentical family members.
• Examination of different effector cell types, such as lymphocytes, T cells, natural killer (NK) cells, and T cell clones.

Main Results:

• Donor lymphocyte transfusion is effective for recurrent, persistent, and mixed chimerism in hematologic malignancies.
• Therapeutic strategies have expanded to include NK cells, NKT cells, and antibody-directed therapies.
• Diverse donor sources and cell types have been employed successfully.

Conclusions:

• Adoptive immunotherapy in chimeric patients is a routine treatment for recurrent hematologic malignancies.
• This approach serves as a prophylactic measure for high-risk leukemia and lymphoma.
• The field continues to evolve with novel cell types and therapeutic strategies.